---
title: "Commit Biologics ApS – Regnskab 2025 og nøgletal"
description: "Commit Biologics ApS (CVR 42642649). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -23,4 mio. DKK, årets resultat -33,8 mio. DKK, egenkapital 37,9 mio. DKK."
canonical_url: "https://datapublica.dk/companies/42642649-commit-biologics-aps/financials"
locale: "da"
route_type: "company_financials"
robots: "index,follow"
content_access: "standard"
---

# Commit Biologics ApS — Regnskab

Commit Biologics ApS \(CVR 42642649\). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -23,4 mio. DKK, årets resultat -33,8 mio. DKK, egenkapital 37,9 mio. DKK.

CVR 42642649

## Seneste regnskabsperiode

- 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • -23365247 • -39469333 • -33781079 • 38807917 • 37898027 • 17

## Regnskabshistorik

- 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -31408009 • -45476820 • -39360775 • 24451213 • 23218018 • 13

- 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -13580251 • -20775186 • -17295813 • 23325997 • 22578793 • 10

- 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • -2722308 • -4447525 • -4315868 • 41012792 • 39874606 • 2

- 2022 • 2021-09-01 • 2022-12-31 • entity • DKK • -2722308 • -4447525 • -4315868 • 41012792 • 39874606 • 3.31

## Højdepunkter fra årsrapporten

- primary activities • Description of key activities of the companyThe company's object is manufacture of pharmaceutical preparations, research and experimental

development within biotechnology. • entity

- development in activities and financial affairs • Significant changes in the company's activities and financial mattersThere have been no significant changes in activities and financial matters.

The gross loss for the year totals DKK -23.365.247 against DKK -31.408.009 last year. Loss from ordinary activities after tax totals DKK -33.781.079 against DKK -39.360.775 last year. Management considers the net loss for the year expected.

Commit Biologics has continued to progress during the past year, advancing its work in complement-mediated immunotherapy. Through focused research and development efforts, the company has further developed its platform and build a pipeline of novel therapeutic candidates.

Looking ahead, the company remains focused on leveraging its platform to support the development of potential therapies for patients with serious diseases. • entity

- subsequent events • Events occurring after the end of the financial yearFollowing the close of the financial year, the company completed a capital increase, raising DKK 32 million to support planned activities and growth initiatives in 2026. • entity

- contingent liabilities • 2.Contractual obligations and contingencies, etc.

Contingent assetsThe company has a tax loss for carryforward of a total amount of t.dk 50.404. Asset value of the tax loss for carryforward amounts to t.dk. 11.089.

Contractual obligations and contingent liabilities

31/12 2025

DKK in thousands

Other contractual obligations

481

Total contractual obligations

481

Total contingent liabilities

0

Total contractual obligations and contingent liabilities

481 • entity